Posters

Effect of EyeMax extended macular vision IOL implantation on reading performance

Poster Details

First Author: B.Qureshi UK

Co Author(s):    S. Robbie                    

Abstract Details

Purpose:

The iolAMD Eyemax mono (Eyemax; London Eye Hospital Pharma) is the first of a new class of intraocular lens designed to optimise the image provided to the macula at eccentricities of up to 8 degrees from the foveal centre. The optics of this device theoretically offer improved visual function in subjects with macular pathology. This small pilot study was designed assess reading performance following implantation with the Eyemax intraocular lens (IOL) in subjects with age-related macular degeneration.

Setting:

London Eye Hospital, 4 Harley St, London UK

Methods:

8 eyes of 7 subjects with �â�‰�¤1 cataract, bilateral, advanced dry age-related macular degeneration (AMD) and preoperative decimal corrected distance visual acuity �â�‰�¥0.60 (CDVA; LogMAR), underwent lens extraction and IOL implantation with a hypermetropic post-operative refractive target. Monocular reading acuity, critical print size and reading speed were assessed using the MNREAD chart after refractive error correction at 1 month post-operatively.

Results:

Post-operative MN read data were unavailable for one subject. In the remainder we observed an improvement in mean reading acuity from 1.07 LogMAR (95% CI: 0.78 �â�€�“ 1.35) to 0.9 LogMAR (95% CI: 0.56 �â�€�“ 1.25). Critical print size improved from 1.04 (95% CI: 0.80 �â�€�“ 1.27) to 0.95 (95% CI: 0.69 �â�€�“ 1.2). Mean reading speed was observed to increase from 28 words per minute (95% CI: 10 �â�€�“ 46) to 44 words per minute (95% CI: 16 �â�€�“ 73), an improvement of 57%.

Conclusions:

By supplying a high quality image across the macula, the iolAMD Eyemax should facilitate reading ability in patients with macular pathology. In this small cohort of patients, with intermediate to severe AMD and minimal cataract, we observed significant improvements in reading performance after Eyemax implantation.

Financial Disclosure:

gains financially from product or procedure presented, receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented, has significant investment interest in a company producing, developing or supplying product or procedure presented